Ajay K. Gopal
Fred Hutch/University of Washington Cancer Consortium · Fred Hutchinson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ajay K. Gopal as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 21:15 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03498612 · Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative DiseasesUniversity of Washington · terminated · Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma · principal investigator
- Ph2NCT02339922 · Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaUniversity of Washington · active not recruiting · Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma · principal investigator
- Ph2NCT02207062 · Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin LymphomaUniversity of Washington · completed · Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma · principal investigator
- Ph2NCT01703949 · Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaUniversity of Washington · active not recruiting · Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma · principal investigator
- Ph2NCT00073931 · Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's LymphomaFred Hutchinson Cancer Center · completed · Lymphoma · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-11 21:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Protocol Review and Monitoring SystemP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · fiscal years 2020 to 2026 · $401,411 awarded in 2026Same name and institution; not confirmed by an ID
- Molecularly Targeted Therapy for LymphomaK24CA184039 · NCI · UNIVERSITY OF WASHINGTON · fiscal years 2014 to 2018 · $171,401 awarded in 2018Same name and institution; not confirmed by an ID
- Radioimmunotherapy for LymphomaP01CA044991 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · fiscal years 2005 to 2015 · $269,552 awarded in 2015Same name and institution; not confirmed by an ID
- Proapoptotic Therapy for B-cell Non Hodgkin's LymphomaR21CA119519 · NCI · UNIVERSITY OF WASHINGTON · fiscal years 2006 to 2007 · $272,362 awarded in 2007Same name and institution; not confirmed by an ID
- OPTIMIZING RADIOIMMUNOTHERAPY FOR NON HODGKIN'S LYMPHOMAK23CA085479 · NCI · UNIVERSITY OF WASHINGTON · fiscal years 2000 to 2005 · $65,389 awarded in 2005Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 21:15 UTC. The ranking covers the 200 most relevant of 65 PubMed records, and a shared surname and initials can bring in a namesake. All 65 on PubMed
- Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma.J Clin Oncol · 20121,170 citationsRCR 30.4
- PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.N Engl J Med · 2014894 citationsRCR 24.0
- 587 citationsRCR 11.0
- 358 citationsRCR 14.1
- 251 citationsRCR 5.8
- Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.Clin Cancer Res · 2018206 citationsRCR 6.0
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Br J Haematol · 2009191 citationsRCR 4.0
- 175 citationsRCR 5.5
- 171 citationsRCR 3.9
- High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma.Blood · 2002165 citationsRCR 3.6